Please use this identifier to cite or link to this item:
Scopus Web of Science® Altmetric
Type: Journal article
Title: Suppression of PDGF-induced PI3 kinase activity by imatinib promotes adipogenesis and adiponectin secretion
Author: Fitter, S.
Vandyke, K.
Gronthos, S.
Zannettino, A.
Citation: Journal of Molecular Endocrinology, 2012; 48(3):229-240
Publisher: Soc Endocrinology
Issue Date: 2012
ISSN: 0952-5041
Statement of
Stephen Fitter, Kate Vandyke, Stan Gronthos and Andrew C W Zannettino
Abstract: Improved glucose and lipid metabolism is a unique side effect of imatinib therapy in some chronic myeloid leukaemia (CML) patients. We recently reported that plasma levels of adiponectin, an important regulator of insulin sensitivity, are elevated following imatinib therapy in CML patients, which could account for these improved metabolic outcomes. Adiponectin is secreted exclusively from adipocytes, suggesting that imatinib modulates adiponectin levels directly, by transcriptional upregulation of adiponectin in pre-existing adipocytes, and/or indirectly, by stimulating adipogenesis. In this report, we have demonstrated that imatinib promotes adipogenic differentiation of human mesenchymal stromal cells (MSCs), which in turn secrete high-molecular-weight adiponectin. Conversely, imatinib does not stimulate adiponectin secretion from mature adipocytes. We hypothesise that inhibition of PDGFRα (PDGFRA) and PDGFRβ (PDGFRB) is the mechanism by which imatinib promotes adipogenesis. Supporting this, functional blocking antibodies to PDGFR promote adipogenesis and adiponectin secretion in MSC cultures. We have shown that imatinib is a potent inhibitor of PDGF-induced PI3 kinase activation and, using a PI3 kinase p110α-specific inhibitor (PIK-75), we have demonstrated that suppression of this pathway recapitulates the effects of imatinib on MSC differentiation. Furthermore, using mitogens that activate the PI3 kinase pathway, or MSCs expressing constitutively activated Akt, we have shown that activation of the PI3 kinase pathway negates the pro-adipogenic effects of imatinib. Taken together, our results suggest that imatinib increases plasma adiponectin levels by promoting adipogenesis through the suppression of PI3 kinase signalling downstream of PDGFR.
Keywords: Adipocytes; Mesenchymal Stem Cells; Humans; Benzamides; Sulfonamides; Hydrazones; Piperazines; Pyrimidines; Receptors, Platelet-Derived Growth Factor; Platelet-Derived Growth Factor; Mitogens; Protein Kinase Inhibitors; Cell Differentiation; Enzyme Activation; Molecular Weight; Adipogenesis; Proto-Oncogene Proteins c-akt; Adiponectin; Imatinib Mesylate; Phosphoinositide-3 Kinase Inhibitors
Rights: © 2012 Society for Endocrinology
RMID: 0020119482
DOI: 10.1530/JME-12-0003
Appears in Collections:Medical Sciences publications

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.